COMPASS Pathways plc (CMPS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Medical - Care Facilities industria. La empresa tiene su sede en London, United Kingdom. El CEO actual es Kabir Kumar Nath.
CMPS tiene fecha de IPO 2020-09-18, 166 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $572.67M.
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
